Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01792050 · ClinicalTrials.gov registry record · Phase 2
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase 2 study, sponsored by NewLink Genetics Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 169
- Enrollment target
NCT01792050 is a Phase 2 study that has completed, run by NewLink Genetics Corporation. The registered enrollment target is 169 participants.
The verdict
NCT01792050, a Phase 2 study, has completed, sponsored by NewLink Genetics Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 169 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effects, good and/or bad, of standard of care therapy (docetaxel or paclitaxel) with or without the addition of 1-Methyl-D-tryptophan (referred to as indoximod) an experimental drug to find out which treatment is better.
Interventions
- DRUG Docetaxel
- OTHER Placebo
- DRUG Paclitaxel
- DRUG Indoximod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2013-02 |
| Est. Completion | 2017-07-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01792050
The ClinicalTrials.gov registry entry for NCT01792050 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewLink Genetics Corporation, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT01792050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01792050 about?
NCT01792050 is a clinical study titled "Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer". The purpose of this study is to compare the effects, good and/or bad, of standard of care therapy (docetaxel or paclitaxel) with or without the addition of 1-Methyl-D-tryptophan (referred to as indoximod) an experimental drug to find out which treatment is better.
What is the current status of trial NCT01792050?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 169 participants. The study started on 2013-02. Estimated completion is 2017-07-07.
What interventions are being tested in trial NCT01792050?
The interventions under investigation include: Docetaxel (DRUG), Placebo (OTHER), Paclitaxel (DRUG), Indoximod (DRUG).
Who is sponsoring clinical trial NCT01792050?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.